BioSpecifics Technologies's revenue for the
three
months ended in Sep. 2020 was $11.26 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2020 was $36.59 Mil.
BioSpecifics Technologies's Revenue per Share for the
three
months ended in Sep. 2020 was $1.53.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $4.97.
Warning Sign:
BioSpecifics Technologies Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of BioSpecifics Technologies was 0.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 26.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, BioSpecifics Technologies's highest 3-Year average Revenue per Share Growth Rate was 58.20% per year. The lowest was -51.80% per year. And the median was 11.00% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioSpecifics Technologies's Revenue
For the Biotechnology subindustry, BioSpecifics Technologies's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioSpecifics Technologies's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Revenue distribution charts can be found below:
* The bar in red indicates where BioSpecifics Technologies's Revenue falls into.
BioSpecifics Technologies Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioSpecifics Technologies Revenue Related Terms
Thank you for viewing the detailed overview of BioSpecifics Technologies's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioSpecifics Technologies (BioSpecifics Technologies) Business Description
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSTC has been successfully added to your 